Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Nov 21, 2025

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Small-cell lung cancer.

Charles M Rudin^1,2, Elisabeth Brambilla³, Corinne Faivre-Finn^4,5

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. rudinc@mskcc.org.

Nature Reviews. Disease Primers

|January 15, 2021

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

<i>SMARCA4, STK11,</i> and <i>KEAP1</i> co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.

bioRxiv : the preprint server for biology·2026

Same author

L1CAM signaling through planar cell polarity drives SOX2 expression and lung adenocarcinoma metastasis.

Nature communications·2026

Same author

Clinicogenomic analysis of <i>EGFR</i>-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.

Science translational medicine·2026

Same author

Hierarchical classification of immune cell transcriptomes at population-scale.

bioRxiv : the preprint server for biology·2026

Same author

Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung Cancer.

JCO precision oncology·2026

Small-cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis. Understanding SCLC

Area of Science:

Oncology
Genomics
Cancer Biology

Background:

Small-cell lung cancer (SCLC) accounts for 15% of lung cancers, characterized by rapid proliferation, early metastasis, and poor outcomes.
SCLC is strongly linked to tobacco carcinogen exposure, with most patients diagnosed at the metastatic stage.
Genomic analysis reveals extensive chromosomal rearrangements and high mutation burden, often involving TP53 and RB1 tumor suppressor gene inactivation.

Purpose of the Study:

To review the biological underpinnings of SCLC, including its heterogeneity and vulnerabilities.
To discuss recent therapeutic advancements and future strategies for SCLC treatment.
To highlight the potential of targeted therapies and immune checkpoint blockade.

Main Methods:

Review of genomic profiling data in human SCLC and murine models.

More Related Videos

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Nov 21, 2025

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

Analysis of SCLC subtypes based on transcriptional regulators.

Examination of factors contributing to tumor evolution, metastasis, and therapeutic resistance.

Main Results:

SCLC exhibits significant intratumoral heterogeneity, influencing tumor progression and treatment resistance.
Novel biological vulnerabilities in SCLC are being identified for targeted therapeutic development.
Immune checkpoint blockade shows promise, benefiting a subset of patients with durable responses.

Conclusions:

Despite slow clinical progress, a deeper understanding of SCLC biology offers new therapeutic avenues.
Targeted therapies and strategies to enhance immune checkpoint blockade efficacy are crucial for improving patient outcomes.
Further research is needed to identify predictive biomarkers and extend the benefits of novel treatments to more SCLC patients.